Key Highlights

● Mirum Pharmaceuticals (MIRM) closed at $87.96 on Monday, down about 1.9% from $89.70, after trading between $84.71 and $91.25.

● Brelovitug met the primary endpoint in the Phase 3 AZURE-1 hepatitis Delta study, with 56% response on the weekly dose.

● The company reported no Grade 3 or higher treatment-related adverse events and no discontinuations from adverse events in the study.

● Mirum plans a Biologics License Application in the first half of 2027, with a possible US launch in late 2027.

Mirum Pharmaceuticals (NASDAQ:MIRM) edged lower on Monday, September 28, closing at $87.96 against $89.70 on Friday, a decline of about 1.9%, even though the company reported positive Phase 3 results for its hepatitis delta drug candidate. The stock traded between $84.71 and $91.25 during the session.

What AZURE-1 Showed

Hepatitis delta is the most severe form of viral hepatitis. It infects only people who already carry hepatitis B and can lead to liver scarring, liver failure and liver cancer. In the Phase 3 AZURE-1 study of 153 treatment-naive patients, brelovitug met its primary endpoint, a combination of virologic response and normalized ALT, a liver enzyme that signals inflammation, at Week 24. The company reported that 56% of patients on 300 mg weekly and 45% on 900 mg every four weeks met it, against 0% for a delayed-treatment control group, with p-values below 0.0001.

Virologic response was 86% and 85% in the two dose groups, and ALT normalization was 63% and 54%. Mirum said there were no Grade 3 or higher treatment-related adverse events and no discontinuations because of adverse events, with injection site reactions in 10% to 19% of treated patients.

The Regulatory Path

Mirum plans to submit a Biologics License Application, the formal request for FDA approval of a biologic medicine, in the first half of 2027 and sees a possible US launch in the fourth quarter of 2027. Brelovitug holds FDA Breakthrough Therapy designation, and the European Medicines Agency has granted PRIME and Orphan designations. Topline results from a second Phase 3 study, AZURE-4, are expected in the fourth quarter of 2026. The company held an investor call at 8:30 a.m. Eastern on Monday.

Good News and a Lower Price

Stocks can fall after positive data. Expectations may already be reflected in the price, and investors may weigh the numbers against competing treatments, but Mirum has not disclosed a reason and this article does not attribute the move to any one factor. Health care was among the few groups to rise on Monday, and Kodiak Sciences (NASDAQ:KOD) reportedly more than doubled on eye-disease data, so Mirum's slip ran against the sector. Major indexes closed in the red. The S&P 500 declined 59.72 points to 7,683.69, the Dow Jones Industrial Average slid 347.11 points to 51,481.51, and the Nasdaq Composite retreated 248.34 points to 26,820.38.

What to Watch for Mirum

Investors will look for fuller AZURE-1 data, including safety detail and how durable responses are beyond Week 24, along with the AZURE-4 readout due in the fourth quarter and progress toward the planned 2027 filing. The company's releases and SEC filings are the best guide to those milestones.

The week ahead includes JOLTS and consumer confidence on Tuesday, PCE Inflation on Wednesday, ISM Manufacturing on Thursday and the September jobs report on Friday, each of which could move yields. The Federal Reserve raised rates on September 16 to a range of 3.75% to 4.00%, and futures suggest the next hike could come as soon as October.